{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-052940","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.722423+00:00","generated_at":"2026-05-24T22:38:36.260470+00:00","sec_items":["5.02","5.07","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AlloVir shareholders approve merger with Kalaris; combined co to trade as KLRS","bullets":["Stockholders voted to approve merger: 3,543,715 for, 368,843 against, 282 abstain out of 3,912,840 votes cast.","2020 Plan amended: share reserve increased by 5% of post-merger outstanding; plan term extended to 10th anniversary of closing.","Combined company to be renamed Kalaris Therapeutics, trading on Nasdaq under ticker KLRS after closing.","Kalaris lead candidate TH103 (anti-VEGF fusion protein) in Phase 1 trial for neovascular AMD; plans for DME and RVO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-052940","json":"https://secwatch.observer/filing/0001193125-25-052940.json","markdown":"https://secwatch.observer/filing/0001193125-25-052940.md","text":"https://secwatch.observer/filing/0001193125-25-052940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525052940/0001193125-25-052940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525052940/d347915d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:38:36.260470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}